Optimal CAB Case Study: Pediatric Dolutegravir
A framework to support new product introduction in national health systems
Resource Library


- May 16
CAB Case Studies from Ethiopia

- Feb 27
Community Statements on DRV/r Use in 2L

- Feb 16
CAB Case Studies from Tanzania

- Feb 16
CAB Case Studies from Zambia

- Feb 16
CAB Case Studies from Nigeria

- Feb 16
CAB Case Studies from Uganda

- Oct 18, 2022
Prevention Product Preference Brief

- Oct 18, 2022
CAB-LA Community Meeting Overview

- Sep 12, 2022
AHD Community Advocacy Video

- Sep 12, 2022
Pediatric DTG Advocacy Video for Communities (English and French)

- Jul 31, 2022
Optimal CAB Case Study: Enabling and Ensuring Equitable HIV Treatment for Women

- Jul 31, 2022
Case Study: Community-Developed HIV Care and Treatment Literacy Improves Uptake of Optimal Medicines

- Jun 16, 2022
AHD Social Media Campaign

- Apr 27, 2022
Pediatric DTG Administration Video for Caregivers (English and French)

- Apr 13, 2022
Adult DRV/r (400/50mg) FAQs for Communities and PLHIV

- Apr 4, 2022
Pediatric DTG Poster (English, French, Swahili)

- Apr 4, 2022
Pediatric DTG FAQs for Caregivers and Communities (English, French, Swahili)

- Apr 4, 2022
Pediatric DTG Administration Poster for Caregivers (English, French, Swahili)

- Apr 4, 2022
Pediatric DTG Pocketbook for Caregivers (English, French, Swahili)